Deutsche Bank’s Acrivon Therapeutics ACRV Stock Holding History

Deutsche Bank’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-541	Closed	-$1.1K	–	3603
2025 Q1	$1.1K	Buy	+541	New	+$2.91K	﹤0.01%	3560
2023 Q3	–	Sell	-4,062	Closed	-$52.6K	–	3696
2023 Q2	$52.6K	Sell	4,062 -1,307	-24%	-$15.8K	﹤0.01%	3468
2023 Q1	$68.1K	Buy	+5,369	New	+$90.1K	﹤0.01%	3466

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Deutsche Bank's ACRV Position: Q2 2025 in Review

Deutsche Bank sold out of Acrivon Therapeutics (ACRV) in Q2 2025, closing a stake of 541 shares — an estimated $1.1K sold.

Deutsche Bank first reported a position in ACRV in Q1 2023 and held it in 3 quarters. The position peaked at $68.1K in Q1 2023. 53 funds tracked by Wall St. Rank hold ACRV as of Q2 2025.

Deutsche Bank reported no remaining Acrivon Therapeutics position as of Q2 2025 after selling out during the quarter.
Deutsche Bank sold 541 Acrivon Therapeutics shares in Q2 2025, an estimated $1.1K.
Deutsche Bank first reported a position in Acrivon Therapeutics in Q1 2023 and held it in 3 quarters.
Deutsche Bank's Acrivon Therapeutics position peaked at $68.1K in Q1 2023.
53 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2025.

Based on Deutsche Bank's 13F filing for Q2 2025, filed 12 Aug 2025.